Pathologies of the brain, of which brain cancer, Alzheimer's disease, Parkinson's disease,
stroke, and multiple sclerosis, are some of the most prevalent, and that presently are poorly …

Alzheimer's disease (AD) represents a particular therapeutic challenge because its
aetiology is very complex, with dynamic progression from preclinical to clinical stages …

Background Traumatic brain injury (TBI) is a leading cause of death and disability
worldwide. Microglial/macrophage activation and neuroinflammation are key cellular events …

Achieving regulation of endogenous gene expression in the central nervous system (CNS)
with antisense oligonucleotides (ASOs) administered systemically would facilitate the …

Sustained silencing of gene expression throughout the brain using small interfering RNAs
(siRNAs) has not been achieved. Here we describe an siRNA architecture, divalent siRNA …

Nucleic acid drugs have the advantages of rich target selection, simple in design, good and
enduring effect. They have been demonstrated to have irreplaceable superiority in brain …

The blood–brain barrier (BBB) is the main obstacle to the effective delivery of therapeutic
agents to the brain, compromising treatment efficacy for a variety of neurological disorders …

ABSTRACT RNA therapeutics comprise a diverse group of oligonucleotide-based drugs
such as antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and short …

Brain metastases encompass nearly 80% of all intracranial tumors. A late stage diagnosis
confers a poor prognosis, with patients typically surviving less than 2 years. Poor survival …

The highly secure blood–brain barrier (BBB) restricts drug access to the brain, limiting the
molecular toolkit for treating central nervous system (CNS) diseases to small, lipophilic …